Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Consensus Recommendation of "Moderate Buy" by Analysts
Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the seven ratings firms that are covering the company...
MarketBeat·23h ago
More News
Acrivon Therapeutics' (ACRV) "Buy" Rating Reiterated at HC Wainwright
HC Wainwright reissued a "buy" rating and set a $19.00 price target on shares of Acrivon Therapeutics in a research report on Tuesday...
MarketBeat·16d ago
Acrivon Therapeutics (NASDAQ:ACRV) Upgraded at Wall Street Zen
Wall Street Zen upgraded Acrivon Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat·20d ago
Acrivon Therapeutics (NASDAQ:ACRV) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen raised Acrivon Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday...
MarketBeat·20d ago
Cantor Fitzgerald Has Positive View of ACRV FY2025 Earnings
Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Free Report) - Cantor Fitzgerald raised their FY2025 earnings estimates for shares of Acrivon Therapeutics in a report issued on Tuesday, November 18th...
Acrivon Therapeutics (NASDAQ:ACRV - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.47) EPS for the quarter, topping analysts' consensus estimates of...
MarketBeat·27d ago
What’s the role of generative AI in drug discovery?
Investing.com -- Generative AI is emerging as a transformative long-term force in drug discovery, a field historically characterized by lengthy timelines, high costs, and low success rates.